RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .
An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan
Background The primary objective of this study was to compare the change from baseline in mean diastolic ambulatory blood pressure ( ABP ) at 24 h post dose ( trough measurement ) after 8 weeks of treatment with irbesartan or valsartan in subjects with mild-to-moderate hypertension . Secondary objectives included comparing the mean changes from baseline in systolic ABP at trough ; 24-h ABP ; morning and night-time ABP ; self-measured systolic blood pressure ( SBP ) and diastolic blood pressure ( DBP ) ; and office-measured SBP and DBP at trough . Design After a 3-week , single blind , placebo lead-in period , 426 subjects were r and omized to receive either irbesartan 150 mg or valsartan 80 mg for 8 weeks . Methods Ambulatory blood pressure measurements were obtained at baseline and at week 8 . Self-measured morning and evening DBP and SBP readings were obtained at home over a 7-day period at baseline and at week 8 . Office-measured seated DBP and SBP measurements were obtained at trough , at baseline , and at week 8 . Results Irbesartan demonstrated significantly greater reductions than valsartan for mean change from baseline in diastolic ABP at trough ( −6.73 versus −4.84 mmHg , respectively;P = 0.035 ) . Irbesartan produced significantly greater reductions than valsartan for mean systolic ABP at trough ( −11.62 versus −7.5 mmHg , respectively;P < 0.01 ) and for mean 24-h diastolic ABP ( −6.38 versus −4.82 mmHg , respectively;P = 0.023 ) and systolic ABP ( −10.24 versus −7.76 mmHg;P < 0.01 ) . Irbesartan also produced significantly greater reductions than valsartan for office-measured seated DBP ( −10.46 versus 7.28 mmHg , respectively;P < 0.01 ) and SBP ( −16.23 versus −9.96 mmHg , respectively;P < 0.01 ) and for self-measured morning DBP ( −6.28 versus −3.75 mmHg , respectively;P < 0.01 ) and SBP ( −10.21 versus −6.97 mmHg , respectively;P < 0.01 ) . Both drugs were well tolerated . Conclusion Irbesartan was more effective than valsartan in reducing DBP and SBP at trough and in providing greater overall 24-h blood pressure-lowering efficacy
RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .